Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes…
| Price | $2.09 |
|---|---|
| Market cap | $79.82M |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NASDAQ |
| 52-week range | 1.56-3.95 |
| Beta | 0.98 |
Explore SERA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.